A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination with Durvalumab (MEDI4736) or Tremelimumab in Patients with Advanced Solid Tumors

Protocol: 
AAAQ8659
Phase: 
I

A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination with Durvalumab (MEDI4736) or Tremelimumab in Patients with Advanced Solid Tumors

The primary purpose of this study is determine a safe dose for the combinations of LY3022855 with durvalumab or LY3022855 with tremelimumab. This study will help answer the following research questions: · What side effects may be experienced when taking LY3022885 with durvalumab or tremelimumab? · How much LY302255, in combination with durvalumab or tremelimumab, should be given to the patients?

Are you Eligible? (Inclusion Criteria)

1. Must have histological or cytological evidence of a diagnosis of cancer that
is
not amenable to curative therapy.
2. Are >=18 years of age.
3. Have discontinued previous treatments for cancer and recovered from the
acute effects of therapy.
4. Have an estimated life expectancy, in the judgment of the investigator, of at
least 12 weeks.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States